226 related articles for article (PubMed ID: 22222052)
21. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
[TBL] [Abstract][Full Text] [Related]
22. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
23. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
[TBL] [Abstract][Full Text] [Related]
24. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
25. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Aziz H; Raza A; Waheed Y; Gill U; Gill ML
Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
[TBL] [Abstract][Full Text] [Related]
26. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G;
J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection.
Reiberger T; Rasoul-Rockenschaub S; Rieger A; Ferenci P; Gangl A; Peck-Radosavljevic M
Eur J Clin Invest; 2008 Jun; 38(6):421-9. PubMed ID: 18489402
[TBL] [Abstract][Full Text] [Related]
28. Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.
Ackefors M; Castedal M; Dahlgard O; Verbaan H; Gjertsen H; Wernerson A; Weiland O
Infect Dis (Lond); 2015 Apr; 47(4):209-17. PubMed ID: 25650729
[TBL] [Abstract][Full Text] [Related]
29. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
30. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.
Werner CR; Egetemeyr DP; Lauer UM; Nadalin S; Königsrainer A; Malek NP; Berg CP
Liver Transpl; 2012 Dec; 18(12):1464-70. PubMed ID: 22941516
[TBL] [Abstract][Full Text] [Related]
31. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
[TBL] [Abstract][Full Text] [Related]
32. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.
Dogan UB; Akin MS; Yalaki S
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1317-20. PubMed ID: 23680912
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
35. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
[TBL] [Abstract][Full Text] [Related]
36. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
[TBL] [Abstract][Full Text] [Related]
37. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
[TBL] [Abstract][Full Text] [Related]
38. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
Romero AI; Lagging M; Westin J; Dhillon AP; Dustin LB; Pawlotsky JM; Neumann AU; Ferrari C; Missale G; Haagmans BL; Schalm SW; Zeuzem S; Negro F; Verheij-Hart E; Hellstrand K;
J Infect Dis; 2006 Oct; 194(7):895-903. PubMed ID: 16960776
[TBL] [Abstract][Full Text] [Related]
39. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
[TBL] [Abstract][Full Text] [Related]
40. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
